Anke Stroet

Publications (2)8.31 Total impact

• Article: Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.

  Anke Stroet, Ralf Gold, Andrew Chan
  Neurology 03/2012; 78(12):933; author reply 933-4. · 8.31 Impact Factor
• Article: Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany.

  Anke Stroet, Claudia Hemmelmann, Michaela Starck, Uwe Zettl, Jan Dörr, Paul Friedemann, Friedmann Paul, Peter Flachenecker, Vinzenz Fleischer, Frauke Zipp, Holger Nückel, Bernd C Kieseier, Andreas Ziegler, Ralf Gold, Andrew Chan
  [show abstract] [hide abstract]
  ABSTRACT: Background: The incidence of therapy-related acute leukaemia (TRAL) in mitoxantrone treatment in multiple sclerosis (MS) is controversially discussed.Methods and results: In a retrospective meta-analysis from six centres, we observed six cases of acute myeloid leukaemia (AML) (incidence 0.41% for patients with mean follow up after end of treatment of 3.6 years, n = 1.156; incidence 0.25% for all patients, n = 2.261). Potential influencing factors such as myelotoxic or glucocorticosteroid pretreatment/cotreatment were present in all but one case of TRAL. Between 1990 and 2010, 11 cases of TRAL were reported to the Drug Commission of the German Medical Association (estimated risk of 0.09-0.13%).Conclusions: Regional differences in reported TRAL incidence may point to confounding cofactors such as administration protocols and cotreatments.
  Therapeutic Advances in Neurological Disorders 03/2012; 5(2):75-9.